Pancreatic Cancer Research

ResearcherFujita Health UniversityNo recent work listed

Hiroyuki Kato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5798-2725; OpenAlex author ID A5003938029. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 14

  1. [A Case of Locally Advanced, Unresectable Pancreatic Cancer with Superior Mesenteric Artery Invasion Treated with FOLFIRINOX plus Radiation Therapy, followed b… First author PMID 37608424↗
  2. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002032↗
  3. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Co-author DOI 10.1097/sla.0000000000004148↗
  4. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factor… Co-author DOI 10.1002/ags3.12427↗
  5. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … First author DOI 10.1097/sla.0000000000003487↗
  6. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… First author DOI 10.1016/j.pan.2019.01.020↗
  7. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… Co-author DOI 10.1097/mpa.0000000000001227↗
  8. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … Co-author DOI 10.1155/2019/5738614↗
  9. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… Co-author DOI 10.3390/cancers11040514↗
  10. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Co-author DOI 10.1097/mpa.0000000000001022↗
  11. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… Co-author DOI 10.3390/cancers10030065↗
  12. [I. The Efficacy of Preoperative Adjuvant Treatment for Pancreatic Ductal Adenocarcinoma Based on the Resectability Criteria according to JPS 7th]. First author PMID 29066676↗
  13. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Co-author DOI 10.1097/mpa.0000000000000335↗
  14. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2013.174↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuji Isaji · 9 shared papers, 2017–2022 · strength 0.80
  2. Shugo Mizuno · 8 shared papers, 2018–2022 · strength 0.72
  3. Yasuhiro Murata · 8 shared papers, 2017–2022 · strength 0.68
  4. Aoi Hayasaki · 8 shared papers, 2017–2022 · strength 0.68
  5. Masashi Kishiwada · 8 shared papers, 2017–2022 · strength 0.68
  6. Naohisa Kuriyama · 7 shared papers, 2018–2022 · strength 0.59
  7. Hiroyuki Sakurai · 7 shared papers, 2018–2022 · strength 0.59
  8. Yoshinori Azumi · 6 shared papers, 2018–2019 · strength 0.47
  9. Akihiko Horiguchi · 2 shared papers, 2021–2023 · strength 0.31
  10. Satoshi Arakawa · 2 shared papers, 2021–2023 · strength 0.31
  11. Hiroki Tani · 1 shared paper, 2023 · strength 0.14
  12. Kazuma Horiguchi · 1 shared paper, 2023 · strength 0.14
  13. Masakazu Yamamoto · 1 shared paper, 2021 · strength 0.13
  14. Yoshiaki Murakami · 1 shared paper, 2021 · strength 0.13
  15. Sohei Satoi · 1 shared paper, 2021 · strength 0.13
  16. Masayuki Sho · 1 shared paper, 2021 · strength 0.13
  17. Hiroki Yamaue · 1 shared paper, 2021 · strength 0.13
  18. Tsutomu Fujii · 1 shared paper, 2021 · strength 0.13
  19. Akio Saiura · 1 shared paper, 2021 · strength 0.13
  20. Kazuyuki Gyoten · 1 shared paper, 2022 · strength 0.13
  21. Itaru Naitoh · 1 shared paper, 2022 · strength 0.12
  22. Hiromi Kataoka · 1 shared paper, 2022 · strength 0.12
  23. Yasuki Hori · 1 shared paper, 2022 · strength 0.12
  24. Michihiro Yoshida · 1 shared paper, 2022 · strength 0.12
  25. Akihisa Kato · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.